NOVO — Oktober 2022
-
Novos pillehåb skuffer analytikere https://www.proinvestor.com/investornyt/885636/novos-pillehab-skuffer-analytikere
-
Novo når endemål med fase 3-forsøg med ugentlig insulin https://www.proinvestor.com/investornyt/885733/novo-nar-endemal-med-fase-3-forsog-med-ugentlig-insulin
-
Novo/Sydbank: Nyt ugentligt insulin kan blive blockbuster https://www.proinvestor.com/investornyt/886154/novo-sydbank-nyt-ugentligt-insulin-kan-blive-blockbuster
-
Aktier/middag: Defensive aktier i plus med Genmab og Novo i toppen https://www.proinvestor.com/investornyt/886625/aktier-middag-defensive-aktier-i-plus-med-genmab-og-novo-i-toppen
-
t amerikanske medicinalselskab Eli Lilly har fået såkaldt fast track-status til lægemiddelkandidaten Tirzepatid i behandling af fedme i USA.
-
Test
-
Roche solgte mindre end ventet - Novo-konkurrentprodukt skuffer https://www.proinvestor.com/investornyt/891555/roche-solgte-mindre-end-ventet-novo-konkurrentprodukt-skuffer
-
Shortpositioner - Danske aktier https://www.proinvestor.com/boards/107056
-
Spændende at høre om hvad Novo melder ud om Wegovy/Catalent på onsdag.
-
Danske aktier: Regnskabssæsonen kulminerer - Investorerne holder øje med Netcompany, ISS, Vestas, APM og Novo Nordisk https://www.proinvestor.com/boards/107403
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind